Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty Drugsmarylandphysicianscarempc infusion site-of-care Pr…
    Ask Trek AI about this page
    CurrentmarylandphysicianscarempcPolicy RX.PA.070.MPC

    Infusion and Injection Services Administered in Unregulated Space

    Customize your policy alerts

    Sign up for marylandphysicianscarempc Policy RX.PA.070.MPC alerts

    Get alerted when Policy RX.PA.070.MPC changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Maryland Physicians Care requirements for site-of-care determination and prior authorization for outpatient infusion and injection services for Maryland Medicaid members, applying to participating and non-participating providers and infusion/home infusion service providers.

    Policy Summary
    Payermarylandphysicianscarempc
    PolicyInfusion and Injection Services Administered in Unregulated Space
    Policy CodePolicy RX.PA.070.MPC
    Change TypeAdds & removes listed medications and biosimilars (see revision log)
    Effective DateApr 1, 2023
    Last ReviewJun 1, 2025
    Next Review DateFeb 1, 2024
    Key ActionObtain site-of-care prior authorization when infusion services are provided in regulated (hospital outpatient) settings; submit supporting medical records for regulated-setting requests.
    SourceLink
    POLICY UPDATE CHANGES

    Addition of Eculizumab biosimilar products and Vyvgart Hytrulo.

    Removal of acute therapy medications - antibiotics, IV iron products and Lemtrada.

    Removal of Botox products from restriction.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Up to 6 monthsInitial auth length
    Up to 1 yearReauthorization length
    1:30 milesRural travel standard
    1:10 milesSuburban travel standard
    1:5 milesUrban travel standard

    Coverage Criteria — Regulated Setting and Site-of-Care Rules

    Regulated setting medical necessity criteria

    Regulated outpatient hospital setting is considered medically necessary when ANY of the following are met:

    Regulated setting criteria

    • Enhanced monitoring or intervention: The individual's complex medical status or therapy requires enhanced monitoring and potential intervention above and beyond the capabilities of the office or home infusion setting; submission of medical records is required.
    • Prior severe infusion-related adverse events: Documentation (eg, infusion records, medical records) of episodes of severe or potentially life-threatening infusion-related adverse events (eg, anaphylaxis, seizure, thromboembolism, myocardial infarction) that have not been responsive to acetaminophen, steroids, diphenhydramine, fluids, infusion rate reductions, or other premedications, thereby increasing risk to the individual when administration is in the home or office setting; submission of medical records is required.
    • Unsuitable home caregiver or environment: Homecare or infusion provider has deemed that the individual, home caregiver, or home environment is not suitable for home infusion therapy (if the prescriber cannot infuse in the office setting); submission of medical records is required.
    • FDA label site-of-care restriction: The prescribed medication has a site-of-care restriction for administration per the FDA-approved label; submission of medical records is required.
    Operational note: Submission of supporting medical records is required to document the criterion met when requesting regulated outpatient hospital setting authorization.

    Site-of-care general coverage

    General coverage stance for site-of-care and medications:

    Preferred and required use of unregulated sites when appropriate: Members are required to utilize alternative (unregulated) sites of care for outpatient infusions and injections (eg, physician office, ambulatory infusion center, home infusion) unless they meet criteria for regulated outpatient hospital setting; each service must be medically necessary and the member must be enrolled on the date of service.
    Prior authorization rules: Site-of-care prior authorization is not required for infusion services administered in unregulated space by participating health professionals, contracted home infusion service providers, and contracted infusion centers. Non-participating providers, and non-contracted home infusion providers and infusion centers must obtain a site-of-care PA prior to rendering services. Site-of-care PA is required for all providers when services are in regulated (hospital outpatient) space.
    Medication-specific medical necessity review: Medications remain subject to separate medication-specific medical necessity review (medical PA) and clinical criteria regardless of site of care.

    Outpatient hospital facility-based infusions and injections are not considered medically necessary unless the member meets at least one of the regulated outpatient hospital setting criteria. These criteria require submission of supporting medical records and include: the member’s complex medical status or therapy requiring enhanced monitoring/intervention beyond office or home capabilities; documented episodes of severe or potentially life‑threatening infusion‑related adverse events (for example, anaphylaxis, seizure, thromboembolism, myocardial infarction) that were not responsive to standard measures such as acetaminophen, steroids, diphenhydramine, fluids, infusion rate reductions, or other premedications; a determination by the homecare or infusion provider that the member, caregiver, or home environment is unsuitable for home infusion when the prescriber cannot provide office administration; or an FDA‑approved label site‑of‑care restriction for the prescribed medication.

    Use of a regulated (hospital outpatient) infusion setting is permitted only when at least one of the specified regulated‑setting medical necessity criteria is met and supporting medical records are provided. Site‑of‑care prior authorization rules apply: participating providers and contracted home infusion/infusion centers generally do not require a site‑of‑care PA for procedures performed in unregulated space, but site‑of‑care PA is required for services in regulated space and for non‑participating providers or non‑contracted infusion providers. Regardless of site of care, medications remain subject to separate medication‑specific medical necessity review and prior authorization.

    Applicable Codes for Infused/Injected Medications

    Applicable HCPCS/Codes for specialty infused/injected medicationsHCPCSCovered
    J1745Injection, infliximab, excludes biosimilar (Remicade), 10 mg
    Q5103Injection, infliximab-dyyb, biosimilar (Inflectra), 10 mg
    Q5104Injection, infliximab-abda, biosimilar (Renflexis), 10 mg
    Q5121Injection, infliximab-axxq, biosimilar (Avsola), 10 mg
    J3380Injection, vedolizumab (Entyvio), 1 mg
    J2350Injection, ocrelizumab (Ocrevus), 1 mg
    J3032Injection, eptinezumab-jjmr (Vyepti), 1 mg
    J2507Injection, pegloticase (Krystexxa), 1 mg
    J1300Injection, eculizumab (Soliris), 10 mg
    J1303Injection, ravulizumab-cwvz (Ultomiris), 10 mg
    1–10 of 24
    1/3

    Provider Actions, Prior Authorization, and Documentation Requirements

    Prior Authorization

    Site-of-care prior authorization rules

    Site-of-care prior authorization is not required when infusion services are administered in unregulated space by participating health professionals, contracted home infusion service providers, or contracted infusion centers. However, non‑participating providers, home infusion service providers and infusion centers must obtain a site-of-care prior authorization from the PA review team before rendering services; site-of-care PA is required for all providers when services are administered in regulated (hospital outpatient) space.

    • No site-of-care PA required for participating providers and contracted home infusion/infusion centers when care is in unregulated space.
    • Non‑participating providers and certain uncontracted providers must obtain site-of-care PA prior to service delivery.
    • Site-of-care PA is required for all providers for infusions administered in regulated (hospital outpatient) settings.
    Step Therapy

    Medication-specific prior authorization required

    Background and Rationale

    Outpatient hospital (regulated) infusion settings are reserved for members whose clinical complexity or therapy requires enhanced monitoring/intervention beyond office or home capabilities, for members with documented episodes of severe or potentially life‑threatening infusion‑related adverse events not responsive to standard measures, when the home environment or caregiver is unsuitable for home infusion, or when the medication’s FDA label includes a site‑of‑care restriction.

    Key Definitions

    Site of Care
    DefinitionChoice for physical location of infusion administration; includes hospital inpatient, hospital outpatient, physician office, ambulatory infusion suite, or home-based setting.
    Common sites listedHospital inpatient; Hospital outpatient; Physician office; Ambulatory infusion suite; Home-based setting.
    Policy relevanceIdentifies locations used to determine site-of-care rules, prior authorization requirements, and when regulated (hospital outpatient) criteria apply.
    Implication for providersProviders must select the appropriate site of care on requests and may need to justify use of regulated settings per medical necessity criteria.
    Medically Necessary / Medical Necessity
    DefinitionService, supply or medicine appropriate and necessary for diagnosis or treatment that meets standards of good medical practice and is not primarily for convenience.

    Initial Authorization for Regulated Infusion Setting

    Initial Authorization

    Initial authorization for regulated infusion setting

    Initial authorization: Authorization for services in a regulated outpatient hospital setting will be granted when the member meets at least one regulated‑setting medical necessity criterion and supporting documentation is submitted.up to 6 months

    Medications requested remain subject to separate medication‑specific prior authorization and clinical review.

    Reauthorization / Continuation Criteria

    Reauthorization

    Reauthorization requirements for regulated infusion settings

    Reauthorization: Prior authorization renewals are reviewed on an annual basis to determine continued medical necessity; documentation must show the individual remains medically inappropriate for administration at alternative sites of care.annual

    All medications remain subject to separate medication‑specific medical necessity review regardless of site of care.

    Step Therapy and Medication Prior Authorization

    RequirementDetails
    Medication-specific prior authorization statusMedications are subject to separate medical necessity review using clinical criteria specific to the medication requested, regardless of site of care.
    Coverage implicationMedication medical necessity review (medical PA) is required whether the drug is administered in regulated (hospital outpatient) or unregulated settings.
    Provider actionProviders must obtain medication-specific prior authorization when required by the drug’s clinical criteria; site-of-care PA rules are separate and do not replace medication PAs.

    Preferred and Allowed Sites of Care

    Note

    Prefer and require unregulated sites unless regulated-setting criteria are met

    Use alternative (unregulated) sites of care—physician office, ambulatory infusion center, or home infusion—by default; the regulated (outpatient hospital) setting is required only when the member meets the policy's regulated‑setting medical necessity criteria.

    • Home infusion is available statewide and not subject to travel distance network access limits.
    • Travel distance standards for infusion centers (urban 1:5 miles, suburban 1:10 miles, rural 1:30 miles) are used when assessing network access for infusion center services.

    Biosimilar Policy Updates

    Billing Rule

    Eculizumab biosimilars added to policy (06/2025)

    Eculizumab biosimilar products have been added to the policy’s list (revision 06/2025) and are included among the applicable injectable therapies; treat these biosimilars like the reference product for coverage and medication-specific medical necessity review.

    • Eculizumab biosimilars (Q5151/Q5152 and related J-codes) are listed among applicable HCPCS codes.
    • Medication-specific PA and clinical criteria still apply to eculizumab and its biosimilars.
    Policy Summary
    Payermarylandphysicianscarempc
    PolicyInfusion and Injection Services Administered in Unregulated Space
    Policy CodePolicy RX.PA.070.MPC
    Change TypeAdds & removes listed medications and biosimilars (see revision log)
    Effective DateApr 1, 2023
    Last ReviewJun 1, 2025
    Next Review DateFeb 1, 2024
    Key ActionObtain site-of-care prior authorization when infusion services are provided in regulated (hospital outpatient) settings; submit supporting medical records for regulated-setting requests.
    SourceLink
    On This Page
    Coverage Criteria — Regulated Setting and Site-of-Care RulesApplicable Codes for Infused/Injected MedicationsProvider Actions, Prior Authorization, and Documentation RequirementsBackground and RationaleKey DefinitionsInitial Authorization for Regulated Infusion SettingReauthorization / Continuation CriteriaStep Therapy and Medication Prior AuthorizationPreferred and Allowed Sites of CareBiosimilar Policy Updates

    Medications administered via infusion or injection remain subject to separate medication-specific medical necessity review (medical prior authorization) regardless of whether the service is provided in an unregulated or regulated site of care.

    • Submit medication-specific PA requests using the clinical criteria applicable to the requested medication.
    • Site-of-care determination does not substitute for medication-level medical necessity review.
    Documentation Required

    Medical records required for regulated setting PA

    When requesting authorization for a regulated (outpatient hospital) infusion or injection setting, submit supporting medical records to document the member’s condition — for example, complex medical status requiring enhanced monitoring, prior severe or potentially life‑threatening infusion‑related adverse events not responsive to standard measures, or documentation that the home caregiver/environment is unsuitable for home infusion.

    • Include infusion records and medical records documenting prior severe infusion‑related adverse events (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction) and failure of standard premedication/management.
    • Provide documentation that the member remains medically inappropriate for administration at alternative (unregulated) sites when requesting renewal.
    Denial Risk

    Prior authorization required — risk of denial if not obtained

    Failure to obtain site-of-care prior authorization for infusion services administered in regulated (hospital outpatient) space will result in the services being subject to PA denial; non‑participating providers and certain unregulated providers that do not obtain required site-of-care PA prior to service may also be at risk for denial or payment reduction.

    • Services delivered in regulated space without prior site-of-care authorization are subject to denial.
    • Non‑participating and uncontracted providers must secure site-of-care PA before rendering services to avoid denial/payment risk.
    Standards referencedMeets standards of good medical practice within the medical community in the service area and considers the most appropriate level of service that can safely be provided.
    ExcludesCare provided primarily for the convenience of the plan member or provider.
    Use in policyApplied to determine medical necessity for site-of-care decisions, prior authorization approvals, and coverage determinations.